Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Cyramza ® (ramucirumab)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
No animal studies have been specifically conducted to evaluate the effect of ramucirumab on female reproduction and fetal development, and there are no studies in pregnant women1
Based on ramucirumab’s mechanism of action, it is likely that ramucirumab will inhibit angiogenesis and may potentially result in adverse effects during pregnancy and postnatal development.1
Avoid the use of ramucirumab in pregnant women, and only use if the potential benefit to the mother justifies the potential risk to the fetus. Counsel women of childbearing potential or women who become pregnant during treatment of the potential risks of ramucirumab to the fetus and for maintaining pregnancy.1
Based on the half-life of ramucirumab, advise females of reproductive potential to avoid getting pregnant while receiving ramucirumab and for at least 3 months after the last dose of ramucirumab.1
Animal Data
Animal models link
angiogenesis
VEGF, and
VEGFR-2
to critical aspects of
female reproduction
embryofetal development, and
postnatal development.2
Lactation Risk Summary
No studies have been conducted to assess ramucirumab’s impact on
milk production
its presence in breast milk, or
its effects on the breast-fed child.1
It is not known whether ramucirumab is secreted in human milk. Human immunoglobulin G is excreted in human milk and due to potential risks to the nursing infant, it is recommended to discontinue nursing or discontinue ramucirumab.1
1. Cyramza [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
VEGF = vascular endothelial growth factor
VEGFR-2 = vascular endothelial growth factor receptor 2
Datum fӧr senaste ӧversyn 2019 M03 20